evidence: The subgroup who received non-mRNA vaccines was more likely to be clinically vulnerable and may be at greater risk of adverse events following vaccination than the general population. [...] "We find no evidence that the risk of cardiac or all cause death is increased in the weeks following vaccination with mRNA vaccines. However, receiving a first dose of a non-mRNA vaccine was associated with an increased risk of cardiac death in young women. Vaccination with the main non-mRNA vaccine used in the UK was stopped for young people following safety concerns in April 2021, and most of the young people who received it would have been prioritised due to clinical vulnerability or being healthcare workers. Therefore, these results cannot be generalised to the population as a whole. [...] Another limitation is the selective administration of the vaccines. Vaccination with the main non-mRNA vaccine used in the UK was stopped for young people following safety concerns in April 2021. Young people who had been vaccinated up to this point were mostly those prioritised, for example, because of clinical vulnerability or being a healthcare worker. The young people who were clinically vulnerable are therefore likely to be at higher risk of mortality than the general population and more vulnerable to the SARS-CoV-2 virus.